Polynovo

Polynovo Aktie

Investor Relations Website
WKN: A12F4T
ISIN: AU000000PNV0
Marktkapitalisierung Help -
Streubesitz 57,69%
KGV -
Index-Zuordnung
-

Polynovo Ltd Unternehmensprofil

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Vorstand

Herr Jan-Marcel Gielen C.A.
CFO & Sekretär der Gesellschaft
Herr Bruce Peatey
Geschäftsführender Direktor
Frau Amy Demediuk
Company Secretary & Chefsyndikus
Frau Kimberley Axon
Verantwortlicher für das Personalwesen
Herr Edward Graubart
Präsident von Nordamerika
Herr Ahmed Hassan
Chief Manufacturing & Verantwortlicher für die Lieferkette

Aktionärsstruktur

86,726%
Freefloat
55,725%
Individuelle Aktionäre
31,001%
Institutionelle Aktionäre

Termine

25.08.2026 Quartalsmitteilung

Stammdaten

Nennwert/Aktie -
Land Australien
Währung AUD
Branche Medizinische Instrumente & Zubehör
Aktientyp -
Sektor Gesundheit
Gattung -
Quelle: Leeway